Leadership & Pay ·
Erasca, Inc. appointed Charles S. Fuchs as President of Research & Development effective August 10, 2026
ERASErasca, Inc.
Erasca, Inc. appointed Charles S. Fuchs as President of Research & Development effective August 10, 2026. Dr. Fuchs brings over three decades of oncology leadership experience from roles at Genentech/Roche and Tubulis GmbH. His compensation package includes a $570,000 annual base salary, a target bonus equal to 45% of base, and a stock option award for 1,300,000 shares vesting over four years. To facilitate this hire, the Board adopted the 2026 Employment Inducement Incentive Award Plan, reserving 6,200,000 additional shares without prior stockholder approval under Nasdaq rules. Erasca operates in the biotechnology industry, focusing on gene editing therapies for genetic diseases.